Christobel Selecky Sells 25,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total value of $187,750.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Christobel Selecky also recently made the following trade(s):

• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The stock was sold at an average price of $5.00, for a total value of $250,000.00.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $7.34 on Friday. The business has a fifty day simple moving average of $2.65 and a two-hundred day simple moving average of $2.55. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $8.28. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of -17.90 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $32.06 million during the quarter, compared to analyst estimates of $31.88 million. As a group, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave a clearer path to resubmit an sBLA for ANKTIVA in papillary non?muscle invasive bladder cancer; ImmunityBio plans additional analyses and a filing soon. Read More.
• Positive Sentiment: HC Wainwright reaffirmed bullish coverage and raised long?term outlook (FY2030 EPS estimate to $0.68), signaling rising analyst optimism about the company’s commercial prospects. Read More.
• Positive Sentiment: Recent company announcements about clinical results and an expansion plan have been cited in coverage characterizing the move as a strong rally, which has attracted momentum buyers. Read More.
• Neutral Sentiment: Short?seller pain and a multi?day rally are amplifying volume and volatility; technical short covering can sustain gains short?term but doesn’t guarantee fundamentals. Read More.
• Neutral Sentiment: Multiple outlets note the stock’s extended run (reported as a 12?day advance in some coverage), suggesting momentum trading is a significant component of the move. Read More.
• Negative Sentiment: Company insiders have sold shares recently (director Christobel Selecky and director Barry J. Simon among reported transactions), which investors often view as a caution signal on near?term risk. Read More.
• Negative Sentiment: High?profile commentators (e.g., Jim Cramer) have advised trimming positions and taking profits, highlighting opinion that the recent run may be speculative. Read More.
• Negative Sentiment: Some analysts warn momentum risks and that regulatory requests could require more data or time than investors expect — a potential downside if the sBLA resubmission is delayed or expanded. Read More.

Analysts Set New Price Targets

IBRX has been the subject of a number of research analyst reports. Jefferies Financial Group boosted their price objective on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. BTIG Research restated a “buy” rating on shares of ImmunityBio in a research note on Thursday. D. Boral Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of ImmunityBio in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Finally, Piper Sandler boosted their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $12.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IBRX. TigerOak Management L.L.C. bought a new stake in ImmunityBio during the fourth quarter worth about $33,000. Wealth Management Associates Inc. acquired a new position in shares of ImmunityBio in the 4th quarter valued at approximately $38,000. Cherry Creek Investment Advisors Inc. bought a new stake in shares of ImmunityBio during the 4th quarter worth approximately $28,000. MOR Wealth Management LLC bought a new stake in shares of ImmunityBio during the 4th quarter worth approximately $494,000. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of ImmunityBio by 31.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 402,639 shares of the company’s stock worth $797,000 after acquiring an additional 95,855 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.